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ABSTRACT
Childhood-onset pulmonary arterial hypertension (PAH)
is considered complex and multifactorial, with relatively
poor estimates of the natural history of the disease.
Strategies allowing earlier detection, establishment of
disease aetiology together with more accurate and
sensitive biomarkers could enable better estimates of
prognosis and individualise therapeutic strategies.
Evidence is accumulating that genetic defects play an
important role in the pathogenesis of idiopathic and
hereditary forms of PAH. Altogether nine genes have
been reported so far to be associated with childhood
onset PAH suggesting that comprehensive multigene
diagnostics can be useful in the assessment.
Identification of disease-causing mutations allows
estimates of prognosis and forms the most effective way
for risk stratification in the family. In addition to genetic
determinants the analysis of blood biomarkers are
increasingly used in clinical practice to evaluate disease
severity and treatment responses. As in genetic
diagnostics, a multiplex approach can be helpful, as a
single biomarker for PAH is unlikely to meet all
requirements. This consensus statement reviews the
current evidence for the use of genetic diagnostics and
use of blood biomarkers in the assessment of paediatric
patients with PAH.
INTRODUCTION
During the last decade, advances in genomic tech-
nologies have accelerated genetic research and
broadened our understanding of basic human
biology. Using genomics approaches to study well-
characterised patient cohorts has revealed the
molecular genetic background of many human dis-
eases. Fast accumulation of knowledge on clinically
relevant genomic variants has started to reshape
clinical practices in several fields of medicine. These
include hereditary cardiovascular diseases such as
cardiomyopathies and channelopathies, where thou-
sands of mutations in over 100 genes have been
found. In these disorders the use of genetic testing is
becoming a standard procedure in the diagnostic
workup. Several international guidelines supporting
the use of genetic testing have been published.1 It
has been shown that these approaches can save costs
by enabling rational follow-up focused on family
members with an identified risk.2 Although genetic
testing has not been widely applied to patients with
familial pulmonary arterial hypertension (HPAH,
hereditary forms of PAH) or idiopathic PAH
(IPAH), there is increasing evidence for its useful-
ness in the diagnostic workup. Other strategies to
individualise patients’ treatments and follow-up care
involve the use of blood biomarkers. Biomarkers are
suggested as potential clinical end points that can
optimise the assessment and treatment of patients.
This consensus statement reviews the current evi-
dence for the use of genetic diagnostics and blood
biomarkers in the assessment of paediatric patients
with pulmonary arterial hypertension (PAH) with
respect to diagnosis, prognosis and treatment.
METHODS
The recommendations given in table 1 relate to the
grading system currently suggested by the European
Society of Cardiology and the American Heart
Association, and was based on paediatric data only
(class, level of evidence). The grading and voting
process within the writing group is outlined in the
executive summary31 of this online supplement.
Computerised searches of the PubMed/MEDLINE
bibliographic database from 1990 to January 2015
were conducted. The developer searched using the
terms ‘genetics of pulmonary hypertension’, ‘paedi-
atric pulmonary hypertension’, ‘genetic diagnostics
in pulmonary hypertension’, ‘genetics of
childhood-onset pulmonary hypertension’, ‘biomar-
kers of pulmonary hypertension’, ‘BNP and chil-
dren’, ‘uric acid and children’, ‘circulating
endothelial cells and children’, ‘biomarkers in chil-
dren with pulmonary hypertension’, ‘circulating
endothelial cells and pulmonary hypertension’,
‘BNP and pulmonary hypertension’, ‘uric acid and
pulmonary hypertension’.
Genetics of PAH
To date, there are at least eight genes associated
with HPAH and IPAH (table 2). From these genes,
bone morphogenetic protein receptor 2 (BMPR2),
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is the major gene associated with HPAH and IPAH. Today over
300 BMPR2 mutations have been identified in patients with
PAH. BMPR2 mutations are estimated to account for approxi-
mately 75% of patients with HPAH and up to 25% of IPAH
cases.3 The penetrance of the disease associated with BMPR2
mutations has originally been considered low. These observa-
tions have been questioned as disease manifestations can take
75 years and phenotypical variability exists. Supporting evidence
for higher penetrance was established through the Vanderbilt
Pulmonary Hypertension Registry where overall penetrance was
27% (female 42% and the male 14%).4 Over 40% penetrance
and high proportion of mutation positive individuals among
patients with HPAH demonstrates that PAH is a genetic disease
comparable with other forms of genetic diseases, i.e., cardiomy-
opathies and channelopathies. BMPR2 mutations are associated
with childhood-onset PAH (table 2).5 6
PAH associated with hereditary haemorrhagic telangiectasia
(HHT) has been identified in multiple studies to associate with
pathogenic mutations in the ACVRL1 gene and in some occa-
sions with Endoglin (ENG), a type III TGF-β receptor.7
ACVRL1 mutations can also be identified in patients with PAH
with no features of HHT. SMAD9 mutations have been sug-
gested as a genetic cause of PAH although existing evidence is
Table 1 Recommendations on the use of genetic testing and biomarkers in children with pulmonary hypertension
Genetics/genetic testing/blood biomarker COR LOE
Genetic counselling is recommended for families with children suffering from severe genetic disorder. This
includes children with IPAH or HPAH17–19
I B
Families of patients with syndromes associated with PAH should be educated on the symptoms of PAH and
recommended to seek clinical evaluation if the child should develop symptoms of PAH
I C
It is recommended to screen asymptomatic PAH mutation carriers, also children, with serial echocardiograms,
and potentially other non-invasive studies
I C
Genetic testing for PAH-associated genes such as ACVRL1, BMPR2, CAV1, ENG and KCNK3 can be useful for
children with PAH of unknown cause to allow definition of aetiology, estimation of prognosis and identification
of family members at risk, and to inform family planning
IIa C
Genetic testing of first-degree relatives of an index patient with PAH and a known disease-causing mutation can
be useful for risk stratification and rationalising surveillance
IIa C
Genetic testing for mutations in EIF2AK4 gene should be considered for children with suspicion of PVOD to allow
for definition of aetiology and identification of family members at risk, and to inform family planning
IIa C
Family members of patients with HPAH who develop new cardiorespiratory symptoms should be evaluated
immediately for PAH
I C
Comprehensive NGS panels targeting all known genetics in PAH can be considered to maximise diagnostic
efficacy and increase cost-effectiveness in genetic diagnostics
IIb C
Genetic testing for PAH-associated genes can be considered for patients with CHD and ‘out of proportion’ PAH
(eg, PAH with small atrial shunt)
IIb C
Measurement of natriuretic peptides BNP or NT-proBNP is recommended to evaluate disease severity, progression
and treatment response in patients with PH20–22
I B
It is uncertain whether analysis of uric acid levels can be used to evaluate disease severity IIb C
Analysis of circulating endothelial cells can be useful to stratify operative risk, to evaluate for progression of disease
and/or response to therapy in children with PAH
IIa B
ACVRL1 (ALK1) activin-like kinase-type 1; BMPR2, bone morphogenetic protein receptor 2; BNP, brain natriuretic peptide; CAV1, caveolin 1; CHD, congenital heart disease; COR,
class of recommendation; EIF2AK4, eukaryotic translation initiation factor 2-α kinase 4; ENG, endoglin; HPAH, hereditary pulmonary hypertension; IPAH, idiopathic pulmonary
arterial hypertension; KCNK3, potassium channel subfamily K, member 3; LOE, level of evidence; NGS, next generation sequencing; NT-proBNP, N-terminal fragment of probrain
natriuretic peptide; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; Definitions for COR and LOE classes can be found in our executive summary table 1
(LINK).
Table 2 Genes associated with childhood-onset pulmonary
hypertension





ACVRL1 (ALK1) IPAH, HPAH ✓ ✓
BMPR1B IPAH ✓
BMPR2 IPAH, HPAH ✓ ✓
CAV1 IPAH, HPAH ✓ ✓
EIF2AK4 PVOD ✓ ✓
ENG IPAH ✓
KCNK3 IPAH, HPAH ✓ ✓
NOTCH3 IPAH ✓
SMAD9 IPAH ✓
High evidence of pathogenicity requires evidence for positive family segregation
between genotype and phenotype or multiple reports supporting causative role in
human disease together with additional evidence such as functional studies.
ACVRL1 (ALK1) activin-like kinase-type 1; BMPR1B, bone morphogenetic protein
receptor 1B; BMPR2, bone morphogenetic protein receptor 2; CAV1, caveolin 1;
EIF2AK4, eukaryotic translation initiation factor 2-α kinase 4; ENG, Endoglin; HPAH,
hereditary pulmonary hypertension; IPAH, idiopathic pulmonary arterial hypertension;
KCNK3, potassium channel subfamily K, member 3; NOTCH3, neurogenic locus notch
homologue protein 3; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive
disease; SMAD9, Smad family member 9.
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mainly based on experimental data derived from functional in
vitro and animal studies.8 Two missense mutations in another
bone morphogenetic protein (BMP) signaling associated gene,
BMPR1B, were identified in children with IPAH.9 An exome
sequencing analysis of a three-generation family with multiple
family members presenting with PAH revealed CAV1 as a novel
gene associated with PAH. Another exome sequencing study on
a family with multiple affected individuals revealed a missense
mutation in a potassium channel gene KCNK3.10 A recent
report suggested that mutations in the NOTCH3 gene could
also cause childhood-onset IPAH.11 A recent breakthrough in
pulmonary veno-occlusive disease (PVOD) has revealed that
mutations in the EIF2AK4 gene play a major role in hereditary
forms of PVOD.12 Genetic testing for mutations in EIF2AK4
gene should be considered for children with suspicion of
PVOD. To date the evidence for causality in human IPAH and
HPAH is considered significant for the following genes:
ACVRL1, BMPR2, CAV1, ENG and KCNK3, whereas the role of
BMPR1B, NOTCH3 and SMAD9 is still unconfirmed (table 2).
There is evidence for genotype-phenotype correlations in
PAH. Multiple studies from different registries have implicated
that carriers of a BMPR2 mutation, irrespective of family
history, develop PAH at a younger age than mutation negative
individuals.13–16 Furthermore, patients with the hereditary form
of PAH developed higher mean pulmonary arterial pressure
(PAP), lower cardiac index, higher pulmonary vascular resistance
(PVR), and were more likely to be treated with parenteral pros-
tanoid therapy or lung transplant when compared with patients
with idiopathic disease. Both children and adults with PAH in
association with a BMPR2 mutation are less likely to respond to
vasodilators and are unlikely to benefit from treatment with
calcium channel blockers. Symptomatic patients with HPAH car-
rying ACVRL1 mutations, most without HHT, have an earlier
age of disease onset and show more rapid disease progression
than patients with BMPR2 mutations.16 A recent study on 54
children with IPAH and HPAH revealed that 25 individuals
(46%) were positive for either BMPR2 (18 patients; 33%) or
ACVRL1 (7 patients; 13%) mutations.6 In this study the 5-year
survival was significantly lower in patients tested positive for
BMPR2 and ACVRL1 mutations. The study outcome correlated
well with previous studies showing earlier onset and more
severe phenotype in mutation positive patients. These studies
suggest that patients with PAH carrying the BMPR2 or ACVRL1
mutation should be considered for more aggressive treatment
strategies.
PAH is a rare complication in many genetic disorders such as
Down syndrome (trisomy 21) where PAH can be caused by the
high incidence of left-to-right shunt, upper airway obstructions
and sleep apnoea. Other disorders where PAH has been
described are congenital heart disease (CHD), 22q11 deletion
syndrome (DiGeorge), VACTERL syndrome, CHARGE syn-
drome, Scimitar syndrome, Noonan syndrome, chromosomal
anomalies associated with congenital diaphragmatic hernia,
Cantu syndrome, autoimmune polyendocrine syndrome, mito-
chondrial disorders including mitochondrial encephalopathy
lactic acidosis and stroke-like episodes, Gaucher disease, and
glycogen storage diseases (GSDI and GSDIII). Establishing the
underlying molecular genetic defect in the majority of these syn-
dromes can be beneficial in determining the exact diagnosis and
estimating prognosis, clinical follow-up as well as treatment
strategies. This recommendation does not focus on the molecu-
lar genetics of these syndromes nor does it recommend testing
of PAH-associated genes in these patients.
Genetic testing in PAH
Considering the possible hereditary nature of PAH, identification
of a child with idiopathic PAH will initiate concerns of disease
susceptibility in other family members, including the parents.
Clinical evaluation of patient and family members will not neces-
sarily establish the aetiology of IPAH and cannot define their risk
to develop PAH later in life. The latter, like in other hereditary
diseases, causes significant distress for the family. Identification of
the genetic background enables effective family member testing
and risk stratification among relatives. Considering the relatively
high penetrance, especially among women, identification of the
causative mutation allows effective clinical monitoring of those
individuals at increased risk for the disease. Similarly, negative
testing in family members following the molecular diagnosis for
an index patient reduces stress burden in family members and
allows discontinuation of future clinical monitoring in these indi-
viduals. This approach could therefore enable the establishment
of cost-effective monitoring and follow-up programmes.2
Follow-up strategies for mutation carrier relatives have to be eval-
uated individually based on the age and sex of the family
member, and existing family history and disease characteristics.
Genetic counselling is recommended for families with chil-
dren suffering from a genetic disorder. Genetic counselling has
to elucidate to the patient and family the rationale for genetic
testing and describe the expected yield of genetic testing.
Counselling also includes addressing the complex issues of
incomplete penetrance and the possibility of finding variants
that currently are classified as variants of unknown significance.
All variant classification scenarios in genetic testing have to be
clear for the referring physician.17 Different end points may
affect the future surveillance of family members. It is also
recommended to discuss concerns about genetic discrimination,
and psychosocial issues of guilt and blame that accompany gen-
etically based diseases. Although there have been concerns that
predictive genetic testing in clinically unaffected children and
adults could provoke anxiety and distress, current studies
suggest instead that it can provide reassurance, lessen uncer-
tainty and promote a sense of control.18 Genetic counselling
should be provided by a healthcare professional with experience
in genetics and PAH. Determining the best age for testing the
asymptomatic children has to be evaluated separately in every
family based on the family history and family’s requests after
counselling. An algorithm for genetic testing of a child with
IPAH or HPAH has been described in figure 1.
An important part of the counselling process is to establish an
inclusive family history and determine the clinical features of the
index patient. This allows comprehensive description of the
disease phenotype and will facilitate interpretation of genetic test
results. Any family history of HHT-like symptoms could point
towards a mutation in the ACVRL1 or ENG gene, whereas at the
same time a negative family history of HHT, does not rule out
the possibility of disease-causing mutation in the ACVRL1 gene.
On the contrary, suspicion of PVOD, especially if recessive inher-
itance is possible, suggests mutations in the EIF2AK4 gene.
Although BMPR2 and ACVRL1 are currently the major disease-
causing genes in PAH, any patient with IPAH or HPAH could
harbour a mutation in any of the other known PAH genes. As the
number of disease-causing genes is expanding there is increasing
rationale to select more effective high-throughput next gener-
ation sequencing (NGS) strategies instead of gene-specific direct
sequencing (Sanger sequencing). NGS-based applications are
already enabling more cost-effective, comprehensive and faster
analysis of causative genes in diagnostic setting. As the field and
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technologies are evolving rapidly there is increasing pressure for
the referring physician to select optimal diagnostic tools to
ensure high-end test quality and interpretation of test results.
NGS strategies are already enabling the analysis of all nine genes
mentioned in this statement with the same costs as single gene
analysis using conventional technologies. Multigene strategies
will provide simultaneous full analysis of BMPR2 and ACVRL1
and can include the analysis of other genes causative for PAH as
well as potential new candidates. Adapting this strategy will allow
for increasing diagnostic power but may also accumulate variant
data impacting future diagnostics. Today’s genetic diagnostics is
increasingly based on public databases, which accumulate variant
information from diagnostics and research. It is becoming a
standard procedure in modern genetic diagnostics to publish
variant data and classifications in public databases such as
ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/).
The use of biomarkers in paediatric PAH
Existing and potential biomarkers in PAH relate to heart failure,
inflammation, haemostasis, vascular remodeling and endothelial
cell-smooth muscle cell dysfunctions. In current PAH guidelines,
brain natriuretic peptide (BNP) and N-terminal fragment of
pro-BNP (NT-proBNP) have been recommended.19 Other prog-
nostic markers such as growth differentiation factor-15, osteo-
pontin and red cell distribution width, are considered emerging
biomarkers of PAH. Anaemia, hypocapnia, elevated uric acid
and C reactive protein levels are unspecific markers of disease
severity. Certain chemokines, matrix metalloproteases and
apelin have been linked to the vascular pathology in PAH and
are considered as potential biomarkers. Circulating endothelial
cells (CECs) and endothelial progenitor cells (EPCs) have
received much attention as markers of disease activity but with
controversial findings. Circulating microparticles and
microRNAs have also been suggested. The majority of the
studies in this field have been done with adults and the role of
most candidate biomarkers in paediatric PAH is unknown. As in
adults, the strongest evidence is on the use of BNP and
NT-proBNP in monitoring disease severity in paediatric PAH.
Biomarkers in children with PAH are likely to be impacted by
additional factors, more so than in adult patients with PAH.
These factors include degree of physical activity, age and/or
developmental stage, gender differences, puberty and nutritional
status. Although several promising markers have been identified
over the past few years, the development of more specific
markers, standardisation and prospective validation are war-
ranted, also in paediatric PAH.
Natriuretic peptides and other plasma protein biomarkers
There is solid evidence in adult and paediatric patients with
PAH that natriuretic peptides have prognostic value.20–22 In
these studies, elevated natriuretic peptides correlated with poor
haemodynamics and increased mortality. The natriuretic pep-
tides atrial natriuretic peptide (ANP) and BNP are synthesised in
the atrial and the ventricular myocardium. These peptides
Figure 1 Algorithm for applying
genetic testing for a child with IPAH or
HPAH, and family members. (–)
negative test result and (+) positive
test result with identification of
pathogenic or likely pathogenic
mutation. If NGS-based comprehensive
analysis of PAH genes is not available
consider gene-specific testing for
BMPR2 and ACVRL1 genes as first-line
diagnostics. *If genetic test reveals a
mutation classified as likely pathogenic
consider new genetic counselling in
5 years to confirm classification and
validity of applied follow-up strategy. #
Follow-up strategies for mutation
carrier relatives have to be evaluated
individually based on the age and sex
of the family member, and existing
family history and disease
characteristics. HPAH, hereditary
pulmonary arterial hypertension; IPAH,
idiopathic pulmonary arterial
hypertension; NGS, next generation
sequencing; PAH, pulmonary arterial
hypertension.
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regulate natriuresis, diuresis and vasomotor tone. Atrial natri-
uretic peptide and BNP are elevated in association with pressure
overload in order to reduce the workload of the heart and
therefore have been found to be elevated in PAH. BNP is pro-
duced as a 108 amino acid prohormone, which is cleaved and
secreted as a biological active sequence (BNP-32) and an inactive
NT-proBNP peptide. BNP-32 has a short half-life of around
20 min and NT-proBNP a longer half-life of several hours, but
both fragments are cleared by the kidney and influenced by
renal function. A recent study elucidates that NT-proBNP levels
correlated with haemodynamic parameters and outcome in PAH
regardless of renal function.23 Large variability of normal
NT-proBNP levels at different ages during childhood has to be
acknowledged when applied in paediatric PAH.24
Cardiac troponin T has also been shown as a significant bio-
marker in PAH correlating independently with mortality.2
Evidence in paediatric population is lacking. Another study on
children with CHD and PAH revealed elevated serum levels of
soluble intracellular adhesion molecule 1.3 In addition growth
differentiation factor-15, galectin-3, endothelins and C reactive
protein are promising as biomarkers in adult PAH, at least with
respect to inflammation. A large number of other inflammatory
proteins have also been suggested as candidates for biomarkers
in PAH. As in genetics, the need for a comprehensive approach
targeting large number of PAH-specific analytes is useful to opti-
mise use of protein biomarkers in everyday clinical practice.
Uric acid
Uric acid is the final degradation product of purines and an
endogenous free radical scavenger that is elevated following
tissue ischaemia and hypoxia. Raised levels have been described
in chronic obstructive pulmonary disease,8 chronic heart failure9
and cyanotic CHD.10 This was underlined by reductions of uric
acid levels in response to chronic vasodilator therapy. Potential
confounding factors, however, include renal dysfunction and
diuretic use and hence uric acid levels must be interpreted in the
context of these factors. The role of uric acid in monitoring
PAH severity and treatment responses may be useful although
further studies are needed.11 25
Circulating endothelial cells
Circulating endothelial cells (CECs) have been established as non-
invasive markers for vascular damage, remodeling and dysfunc-
tion. CECs have been measured in children with IPAH and PAH
associated with CHD, before and after treatment.26 Rising CEC
counts predicted clinical deterioration, suggesting that CECs may
be an important tool to evaluate prognosis.26, 27 Another study
reported elevated levels of CECs associated with reversible
APAH-CHD in children.27 These studies26, 27 involved analysis of
soluble biomarkers, and determined that markers of angiogenic
cytokines, inflammation or endothelial microparticles were not
able to predict PAH reversibility. These studies suggest that circu-
lating CECs could be a potential biomarker in the assessment of
paediatric PAH. On the other hand, some studies have failed to
establish any correlation between CECs and PAH.6 28 The lack
of standards for cell isolation and characterisation methods as well
as differences in the pathological mechanisms of the investigated
patients may contribute to the existing discrepancies.
Conclusions
Emerging evidence is accumulating supporting the use of genetic
testing and blood biomarkers in paediatric PAH to individualise
diagnostics,32 prognostics and therapy.33 In addition, genetic
testing supports efficient risk stratification in family members. As
the number of genes and biomarkers associated with PAH is accu-
mulating, we need more comprehensive diagnostic approaches in
both fields. In addition to new diagnostic technologies, advanced
experimental approaches and patient registries including multi-
centre approaches are needed, to strengthen current evidence
and develop future recommendations.
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